肾集合管癌预后不良的综合分析

doi:10.3969/j.issn.1006-7795.2013.03.009

首都医科大学学报 ›› 2013, Vol. 34 ›› Issue (3): 368-371.doi: 10.3969/j.issn.1006-7795.2013.03.009

肾集合管癌预后不良的综合分析

张沂南¹, 王国民², 金讯波¹, 刘宇军², 赵南³, 付云峰⁴

1. 山东大学附属省立医院泌尿微创中心, 济南 250021;
2. 复旦大学附属中山医院泌尿外科,上海 200032;
3. 聊城市人民医院泌尿外科,山东聊城 252000;
4. 山东省五莲县中医院泌尿外科,山东五莲 262300

收稿日期:2013-01-20 出版日期:2013-06-21 发布日期:2013-06-17
通讯作者: 金讯波 E-mail:jinxunbo@163.com

Collecting duct carcinoma of the kidney: the analysis of its poor prognosis

ZHANG Yinan¹, WANG Guomin², JIN Xunbo¹, LIU Yujun², ZHAO Nan³, FU Yunfeng⁴

1. Minimally Invasive Urology Center, Provincial Hospital Affiliated to Shandong University, Jinan 250021, China;
2. Department of Urology, Zhongshan Hospital, Fudan University, Shanghai 200032, China;
3. Department of Urology, Liaocheng People's Hospital, Liaocheng 252000, Shangdong Province, China;
4. Department of Urology, Wulian Chinese Medicine Hospital, Wulian 262300, Shandong Province, China

Received:2013-01-20 Online:2013-06-21 Published:2013-06-17

摘要/Abstract

摘要：

目的综合分析肾集合管癌的预后及其预后不良的原因。方法回顾性分析4家医院1 013例肾癌中9例肾集合管癌患者的临床、病理资料、综合治疗情况及随访资料。结果 9例集合管癌患者,占同期肾癌的0.888%。其中男6例,女3例,平均年龄60.8岁(37~84岁)。因腰痛、血尿、腹部肿块就诊者6例,无症状肾癌3例。平均肿瘤体积为8.2 cm×6.7 cm×5.9 cm。肿瘤生长呈现肾内转移(5例)、血行转移(6例)、淋巴转移(5例)、直接浸润(2例)及远处转移(1例)等高度恶性生物学行为。临床分期中6例为IV期,I期仅有3例。5例行根治性肾切除术(1例为手助腹腔镜根治性肾切除术),4例行姑息性切除术(1例为手助腹腔镜姑息性肾切除术)。7例行辅助免疫治疗,2例行补救性化疗。平均随访时间13.7个月(7~22个月),6例死亡患者平均生存时间12.7个月。结论肾集合管癌预后不良,其高度恶性的生物学行为是肾集合管癌预后不良的基础原因;目前各医疗机构对肾集合管癌的认识程度差异有统计学意义,治疗方式缺乏特异性,是肾集合管癌预后不良的另一重要原因。随着病例的累积和对于肾集合管癌认知程度的提高,将更加准确的评估和理解肾集合管癌的预后。

关键词: 肾肿瘤, 肾癌, 肾集合管癌, 预后

Abstract:

Objective To analyze the prognosis of collecting duct carcinoma (CDC) of the kidney, and the possible reasons that caused its poor prognosis.Methods Through a multicenter retrospective study, the clinical, pathological, operational and adjuvant therapeutic data of 9 CDC cases out of 1 013 renal cell carcinoma (RCC) cases from 4 institutions were recorded and analyzed.Results Nine CDC cases, 0.888% of the total RCC cases, were finally confirmed, in which there were 6 male and 3 female CDC patients with the mean age of 60.8 (range from 37 to 84) years old. Lumbodynia, hematuria, abdominal masses were observed in 6 cases. Three of 9 cases were in AJCC clinical stage I, and the other 6 in stage IV, with the mean tumor volume of 8.2 cm×6.7 cm×5.9 cm. Intrarenal metastasis (5 cases), hematogenous metastasis (6 cases), regional lymph nodes metastases (5 cases), local invasion (2 cases) and liver metastasis (1 case) were histologically observed. Five cases underwent radical nephrectomy (1 case of hand-assistant laparoscopic radical nephrectomy) and 4 underwent palliative nephrectomy (1 case of hand-assistant laparoscopic palliative nephrectomy). Seven cases underwent adjuvant immunotherapy, and 2 cases underwent salvage chemotherapy. The mean follow-up period was 13.7 months (ranged from 7 to 22 months); the mean survival time of 6 patients was 12.7 months.Conclusion The prognosis of CDC was poor. The highly aggressive biological behavior is basically responsible for its prognosis. Due to lack of knowledge of the CDC, the treatment for CDC had no specificity. With the accumulation of the reported cases, the understanding of CDC's prognosis would be more objective.

Key words: renal tumor, renal cell carcinoma, collecting duct carcinoma of the kidney, prognosis

中图分类号:

R 737.11

张沂南, 王国民, 金讯波, 刘宇军, 赵南, 付云峰. 肾集合管癌预后不良的综合分析[J]. 首都医科大学学报, 2013, 34(3): 368-371.

ZHANG Yinan, WANG Guomin, JIN Xunbo, LIU Yujun, ZHAO Nan, FU Yunfeng. Collecting duct carcinoma of the kidney: the analysis of its poor prognosis[J]. Journal of Capital Medical University, 2013, 34(3): 368-371.

参考文献

[1] 马建辉.肾细胞癌诊断治疗指南[M].北京:人民卫生出版社,2006: 37－38.

[2] Tokuda N, Naito S, Matsuzaki O, et al. Collecting duct (Bellini duct) renal cell carcinoma: a nationwide survey in Japan[J]. J Urol, 2006, 176(1): 40-43.

[3] Karakiewicz P I, Trinh Q D, Rioux-Leclercq N, et al.Collecting duct renal cell carcinoma: a matched analysis of 41 cases[J]. Eur Urol, 2007, 52(4):1140-1145.

[4] 孔祥田,曾荔,宓培,等.肾集合管癌的临床病理研究[J].中华外科杂志, 2000, 38(9):719.

[5] Yousef G M, Ejeckam G C, Best L M, et al. Collecting duct carcinoma associated with oncocytoma[J]. Int Braz J Urol, 2005, 31 (5): 465-467.

[6] Matei D V, Rocco B, Varela R, et al. Synchronous collecting duct carcinoma and papillary renal cell carcinoma: a case report and review of the literature[J]. Anticancer Res, 2005, 25 (1B): 579-586.

[7] 孔祥田,曾荔,宓培,等.肾集合管癌10 例分析[J].中华肿瘤杂志,2001,23(2):162-164.

[8] Ansari J, Fatima A, Chaudhri S, et al. Sorafenib induces therapeutic response in a patient with metastatic collecting duct carcinoma of kidney[J]. Onkologie, 2009, 32(1－2):44-46.

[9] Miyake H, Haraguchi T, Takenaka A, et al. Metastatic collecting duct carcinoma of the kidney responded to sunitinib[J]. Int J Clin Oncol, 2011,16(2):153-155.

[10] Bagrodia A, Gold R, Handorf C, et al. Salvage paclitaxel chemotherapy for metastatic collecting duct carcinoma of the kidney[J]. Can J Urol, 2008, 15(6):4425-4427.

[11] 迟强,于满,王志勇,等.保留肾单位手术治疗双肾细胞癌十例临床分析[J].中华肿瘤防治杂志,2012,19(22):1745-1747,1760.

[12] 张慕淳,张赟,王金辉,等.微血管计数和侵入在肾细胞癌中的表达及意义[J].中国医科大学学报,2011,40(9):794--796.

[13] Vázquez-Lavista L G, Uribe-Uribe N, Gabilondo-Navarro F.Collecting duct renal cell carcinoma: two different clinical stages, two different clinical outcomes[J]. Urol Int, 2008, 81(1):116-118.

[14] Pepek J M, Johnstone P A, Jani A B. Influence of demographic factors on outcome of collecting duct carcinoma: a Surveillance, Epidemiology, and End Results (SEER) database analysis[J].Clin Genitourin Cancer, 2009, 7(2): E24-27.

[15] 朱庆强,王中秋,朱文荣,等. 肾集合管癌的多层螺旋CT诊断[J]. 中华医学杂志,2012, 92(27):1922-1925.

肾集合管癌预后不良的综合分析

Collecting duct carcinoma of the kidney: the analysis of its poor prognosis

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王荣荣, 田俊萍. 急性冠脉综合征患者血清钙与心血管预后的关系[J]. 首都医科大学学报, 2023, 44(1): 154-160.
[2]	贾静, 陈文明, 李燕郴. 多发性骨髓瘤伴中枢侵犯临床特征及预后分析[J]. 首都医科大学学报, 2023, 44(1): 161-166.
[3]	于天宇, 姜世敏, 高红梅, 邹古明, 李文歌. 糖尿病肾病慢性肾脏病4期患者肾脏临床及病理因素与预后的关系[J]. 首都医科大学学报, 2022, 43(5): 707-712.
[4]	郭康林, 程一春, 葛树旺, 徐钢. IgA肾病国际风险预测工具在中国人群中的预测效果评价[J]. 首都医科大学学报, 2022, 43(5): 713-719.
[5]	谷强, 余孝君, 张津. 高龄与中低龄老年轻型缺血性脑卒中临床特点及预后分析[J]. 首都医科大学学报, 2022, 43(3): 474-479.
[6]	周巧云, 黄晓武, 夏恩兰, 赵玉婷, 黄睿. 子宫动脉栓塞后宫腔粘连的生殖结局分析[J]. 首都医科大学学报, 2022, 43(3): 490-494.
[7]	苗祖霈, 张迎花, 肖克令, 司瑾, 张浩宇, 李静. 肥胖程度对急性ST段抬高型心肌梗死患者预后的影响[J]. 首都医科大学学报, 2022, 43(2): 192-198.
[8]	孙婧, 史幼梧, 贾军, 杨颖, 孙志伟, 杜丰, 余靖, 肖艳洁, 张晓东. 血液炎症相关指标在晚期胰腺癌中的预后价值[J]. 首都医科大学学报, 2022, 43(2): 299-304.
[9]	刘洋, 吴玉梅, 何玥, 樊蓓, 王雁, 赵辉, 王明. ⅠB期子宫颈癌国际妇产科联盟2018新分期的合理性验证及评估[J]. 首都医科大学学报, 2021, 42(6): 1026-1032.
[10]	王莉, 张国军. 血清神经元特异性烯醇化酶与外伤性脑损伤患者及临床特征的关系[J]. 首都医科大学学报, 2021, 42(5): 715-720.
[11]	来璇, 张爱华. 代谢综合征对慢性肾脏病患者生存预后的影响[J]. 首都医科大学学报, 2021, 42(4): 609-614.
[12]	王欣, 张俊璇, 高健, 石汉平. 免疫营养改善肿瘤患者预后[J]. 首都医科大学学报, 2020, 41(6): 1019-1024.
[13]	刘军, 曹庆飞, 叶雄俊, 陈伟男, 赵海岳, 佟明, 王银银, 黄晓波, 常智杰. CREPT在肾癌组织中的表达及其与预后的关系[J]. 首都医科大学学报, 2020, 41(4): 552-557.
[14]	吴西抗, 王跃, 贺慧颖. 上尿路尿路上皮癌Slit引导配体3的表达与临床病理特征以及预后的关系[J]. 首都医科大学学报, 2020, 41(3): 354-359.
[15]	曹迪, 李先亮, 张荟, 贺强. 影响肝门部胆管癌术后远期预后的因素[J]. 首都医科大学学报, 2020, 41(3): 439-443.